Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $108.3 million.

  • Myriad Genetics' Accumulated Expenses fell 2.61% to $108.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.3 million, marking a year-over-year decrease of 2.61%. This contributed to the annual value of $119.0 million for FY2024, which is 4.48% up from last year.
  • Per Myriad Genetics' latest filing, its Accumulated Expenses stood at $108.3 million for Q3 2025, which was up 7.65% from $100.6 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Accumulated Expenses peaked at $164.3 million during Q2 2023, and registered a low of $83.1 million during Q1 2021.
  • Its 3-year average for Accumulated Expenses is $116.0 million, with a median of $111.2 million in 2024.
  • As far as peak fluctuations go, Myriad Genetics' Accumulated Expenses skyrocketed by 149.54% in 2021, and later tumbled by 47.73% in 2022.
  • Quarterly analysis of 5 years shows Myriad Genetics' Accumulated Expenses stood at $161.7 million in 2021, then plummeted by 41.68% to $94.3 million in 2022, then grew by 20.78% to $113.9 million in 2023, then rose by 4.48% to $119.0 million in 2024, then declined by 2.61% to $108.3 million in 2025.
  • Its Accumulated Expenses was $108.3 million in Q3 2025, compared to $100.6 million in Q2 2025 and $112.1 million in Q1 2025.